In vitro studies with AZD5153, a novel BRD4 inhibitor, demonstrated repolarization of M2 macrophages to M1 and activation of CD8+ T lymphocytes, while also sensitizing ovarian cancer cell lines to anti-PD-L1 antibodies [137]. Here, CD274 is linked to ovarian carcinoma.